CTX-7144

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCTX-7144
Drug Alias Nameanti-NKp30/anti-HER2 bispecific NK-cell engager (Compass Therapeutics)anti-NKp30/anti-HER2 bispecific antibody (Compass Therapeutics)CTX-7144
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionNatural killer cell p30-related protein agonistsReceptor protein-tyrosine kinase erbB-2 modulators
TargetsNatural killer cell p30-related proteinReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsColonic NeoplasmsBreast NeoplasmsLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCompass Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCompass Therapeutics LLC
Active IndicationsN/A
Inactive IndicationsColonic NeoplasmsBreast NeoplasmsLymphoma, Non-Hodgkin +[4] 

Other Information

ATC CodeN/A
Related LinksN/A